Crossmark

Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B

Published Online: 2026-05-22

Authors

Takeuchi, Mariko

Okimoto, Yoshie

Fukushima, Makoto

Hirano, Harumi

Ogiwara, Hideaki
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP21cm0106185)

Kobayashi Foundation for Cancer Research

Ono Pharmaceutical (C2022-129)
License Information

Text and Data Mining valid from 2026-05-22

Accepted Manuscript valid from 2026-05-22
More Information

Article History

Received: 7 February 2026

Accepted: 13 May 2026

First Online: 22 May 2026

Competing interests

: H.O. received research grants from Ono Pharmaceutical Co., Ltd. during the conduct of the study. The other authors declare no competing interests.

Document is current